EGFR and non-small cell lung carcinoma: Combined inhibition of MET and VEGF enhanced antitumor activity of EGFR TKIs in EGFR/MET co-altered NSCLC by disrupting this loop in a synergistic manner, thereby weakening downstream signal transduction, inhibiting proliferation, and impairing angiogenesis (Fig. 7).